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============

Adults with diabetes have an increased prevalence of coronary heart disease compared with non-diabetic individuals \[[@CR1]--[@CR4]\]. Intensive control of hyperglycaemia retards diabetic microvascular complications (e.g. retinopathy, nephropathy and neuropathy) \[[@CR5]\], but beneficial macrovascular effects (coronary atherosclerosis) are less apparent \[[@CR6]\]. Long-term outcomes of revascularisation are disappointing, irrespective of the mode: angioplasty, stenting or coronary artery bypass grafting \[[@CR1], [@CR7], [@CR8]\].

The autologous saphenous vein (SV) is used routinely as a conduit for coronary artery bypass grafts. Occlusions caused by intimal hyperplasia are common \[[@CR9]--[@CR11]\], with only ∼50% of grafts patent after 10 years and fewer in diabetic patients \[[@CR12]\]. Implantation of the SV graft immediately exposes it to arterial pressure, with profound effects on endothelial cell (EC) and smooth muscle cell (SMC) biology. Loss of homeostatic regulation due to EC damage promotes SMC proliferation and migration in the graft wall, culminating in intimal hyperplasia and graft occlusion \[[@CR13]\].

Insulin effectively controls blood glucose but can itself stimulate SMC proliferation and migration \[[@CR14]\], increasing neointima formation in balloon-injured arteries of normal and diabetic rats \[[@CR15]--[@CR17]\]. Insulin also reportedly enhanced neointima formation in organ-cultured SV in tissue from five patients \[[@CR18]\]. Insulin acting on SV-SMCs may therefore contribute to the pathogenesis of intimal hyperplasia in insulin-dependent diabetic patients.

Human proinsulin C-peptide is a 31-amino-acid peptide that links the A and B chains of proinsulin, ensuring its correct folding \[[@CR19]--[@CR21]\]. C-peptide is cleaved from proinsulin and released into the circulation with insulin in equimolar concentrations. Early studies reported no biological function of C-peptide \[[@CR22]\], an observation supported by lack of interspecies conservation of the C-peptide sequence, both in chain length and amino acid composition. However, it is now apparent that human proinsulin C-peptide is biologically active and modulates cellular function \[[@CR20]\]. Type 1 diabetic patients receive insulin therapy from an early stage, and the majority of type 2 patients over time also require insulin. Exogenously administered insulin does not contain C-peptide. Low sustained concentrations of C-peptide are beneficial \[[@CR23]--[@CR25]\], and chronic administration of replacement C-peptide with insulin ameliorates microvascular complications in animal models and type 1 diabetic patients \[[@CR19], [@CR20], [@CR26]\]. A combination of insulin and C-peptide may therefore provide a more effective treatment for diabetic patients than insulin alone.

Here we explored the interplay between human insulin and proinsulin C-peptide on intimal hyperplasia in organ-cultured SVs from patients without diabetes and on the two key cell types involved in neointima formation, ECs and SMCs, to resolve their independent and joint cell-type-specific effects.

Methods {#Sec2}
=======

**Materials** Cell culture reagents were purchased from Invitrogen (Paisley, UK), except FBS from LabTech International (Ringmer, UK). Proinsulin C-peptide, insulin and PDGF-BB were from Sigma (Poole, UK). PD98059 and LY294002 were from Calbiochem (Nottingham, UK). Migration assay chambers were from BD Biosciences (Oxford, UK).

**Tissue and cell culture** Samples of SV and internal mammary artery (IMA) were obtained from non-diabetic patients undergoing elective coronary artery bypass grafting at the Leeds General Infirmary, with local ethical committee approval and informed patient consent. The study was carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000. Organ cultures were performed using undistended SV as we have described previously \[[@CR27]\] in the absence or presence of insulin, alone or with C-peptide. Segments were fixed and processed to 10 μm. Neointimal thickness was determined using computational analysis on high field magnification at 60 μm intervals along each section by two independent observers.SMCs were cultured from human SV, IMA and aortic root by an explant technique as we have described previously \[[@CR28]\]. SMCs were maintained at 37°C in DMEM containing 25 mmol/l glucose and 10% FBS in a humidified atmosphere of 5% CO~2~ in air. SV-ECs were harvested by collagenase digestion and cultured as described previously \[[@CR29]\]. Experiments were performed on cells of passage number 2--6 from different patients.

**Proliferation assays** SV-EC proliferation assays were performed by seeding cells from different patients in 24-well culture plates at a density of 10,000 per well in full endothelial growth medium (20% FBS). After 30--32 h incubation cells were quiesced in medium containing 1% FBS for 16 h. Cells were then exposed to control growth medium (1% or 10% FBS as appropriate) and selected concentrations of insulin, C-peptide or in combination. Medium and drugs were replaced on days 2 and 4 and viable cell number determined in triplicate wells on day 5 using Trypan Blue and a haemocytometer.SV-SMC and IMA-SMC proliferation assays were performed essentially as described previously \[[@CR28]\]. After plating (10,000 cells per well), cells were incubated overnight in full growth medium, then quiesced in serum-free medium for 3 days before transfer to control growth medium (DMEM with 0.2% FBS and 10 ng/ml platelet-derived growth factor) alone or with appropriate supplements (insulin and/or C-peptide). Medium and drugs were replaced on days 2 and 4 and viable cell number determined in triplicate wells on the appropriate day (usually day 7).

**Migration assays** SV-EC migration was investigated in six-well plates using a modification of a 'scratch wound' method \[[@CR30]\]. Briefly, duplicate scratches were made with a sterile 1 ml pipette tip in confluent endothelial monolayers, reference points etched in the dishes and images were captured (0 h). Cells were then exposed to the relevant media with appropriate stimuli in a tissue-culture incubator for an additional 24 h. Further images were then captured by aligning the dishes with the reference point made at time 0 h, and a second image acquired. Distances of each scratch closure were determined by measuring the cell-denuded area at equal intervals along the wound at each time point for each treatment condition.SV-SMC migration was studied using a modified Boyden chamber technique, as we have described previously \[[@CR28]\]. Cells (100,000) from different patients were loaded in the upper chamber in medium supplemented with 0.4% FBS. The lower chamber contained 0.4% FBS with appropriate supplements (insulin and/or C-peptide). After incubation for 6 h at 37°C in a tissue-culture incubator, duplicate membranes were processed and evaluated by counting migrated cells on the underside of the membrane in 10 random fields under high power (×400) light microscopy \[[@CR28]\].

**Immunoblotting** Serum-starved cells were exposed to serum-free medium containing insulin and/or C-peptide for 15 min before preparing whole cell homogenates and immunoblotting as described previously \[[@CR31]\]. Phosphorylation of Akt (Ser473) and extracellular signal-regulated kinase (ERK) (Thr202/Tyr204) was determined using phospho-specific and expression antibodies (Cell Signaling Technology, Hitchin, UK). Immunolabelled bands were visualised by chemiluminescence and densitometric analysis performed as previously described \[[@CR32]\].

**PCR arrays** Serum-deprived SV-SMCs were exposed to 0.4% FBS alone or supplemented with 100 nmol/l insulin for 6 h before extracting RNA and performing first-strand cDNA synthesis \[[@CR33]\]. The cDNA was confirmed to be of suitable quality for array analysis using the SuperArray QC PCR array (SABiosciences) and the ABI 7500 Real-Time PCR System. Samples of cDNA were then analysed using the Insulin Signalling Pathway Array (SABiosciences). Cycle threshold (C~t~) values were obtained using Sequence Detection Software SDS v1.2.3 (Applied Biosystems) and data analysed by comparing C~t~ values of 84 insulin pathway genes with those of five different housekeeping genes using the SuperArray PCR array analysis software (SABiosciences).

**Real-time PCR** Real-time RT--PCR performed as described previously \[[@CR33]\] using the ABI 7500 Real-Time PCR System with the following human Taqman primer/probe sets: sterol regulatory element binding transcription factor 1 (SREBF1) (product number Hs01088691_m1), IGF 1 receptor (IGF1R) (Hs00541255_s1), sorbin and SH3 domain containing protein 1 (SORBS1) (Hs00908953_m1) and GLUT4 (Hs00168966_m1). Data were expressed as a percentage of hypoxanthine phosphoribosyltransferase 1 (*HPRT1*) mRNA levels (Hs99999909_m1 primers) using the formula $\documentclass[12pt]{minimal}
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**SREBF1 gene silencing** SV-SMCs were transfected with a combination of four different SREBF1-targeted siRNA oligonucleotides (100 nmol/l) (SMARTPool; Dharmacon, Cramlington, UK) using Lipofectamine 2000 transfection reagent (Invitrogen), as described previously \[[@CR34]\]. Control cells were transfected in the absence of siRNA (mock transfected). Effects on protein levels were determined by immunoblotting with mouse monoclonal anti-SREBF1 antibody (ab3259, Abcam), using the method described above. The effects of *SREBF1* gene silencing on SV-SMC migration were determined 36 h after transfection.

**Statistical analysis** All data are expressed as means ± SEM, with *n* representing the number of experiments on cells/tissue from different patients. Data were analysed as ratios using repeated measures one-way ANOVA with the Newman--Keuls post hoc test, using GraphPad Prism software ([www.graphpad.com](http://www.graphpad.com)). *p* \< 0.05 was considered statistically significant.

Results {#Sec3}
=======

**Neointimal thickening in organ-cultured human SV** The ability of insulin to modulate neointima formation was investigated using organ-cultured human SV from ten different patients (Fig. [1](#Fig1){ref-type="fig"}). Mean neointima thickness was 10.4 ± 1.4 µm (median 11.7 µm, range 5.2--16.6 µm) after 14 days' incubation and increased by 70% (*p* \< 0.01) following supplementation with 100 nmol/l insulin (mean 17.7 ± 2.6 µm, median 16.7 µm, range 6.5--31.4 µm). Treatment of SV cultures with C-peptide (10 nmol/l) together with insulin (100 nmol/l) prevented the increase in neointima (mean 8.8 ± 1.36 µm, median 8.9 µm, range 4.8--15.5 µm). Fig. 1Effect of insulin and C-peptide on neointimal thickness in organ-cultured human SV. SV segments were cultured for 14 days in 30% FBS alone (control) or supplemented with 100 nmol/l insulin and/or human C-peptide (10 nmol/l). **a** Representative sections of 14-day cultured segments, stained with haematoxylin and eosin. Scale bars, 30 μm. I, intima; M, media; NI, neointima. **b** Image analysis of full-length SV sections to calculate mean neointima thickness. Scatter plot shows individual values from ten different patients, with data from the same patients linked. \*\*\**p* \< 0.001 (*n* = 10)Proliferation and migration of ECs promote re-endothelialisation of the damaged vessel wall, thereby limiting neointimal development. By contrast, SMC proliferation and migration contribute to neointimal development. We therefore investigated the effects of insulin and C-peptide on SV-EC and SV-SMC proliferation and migration.

**Endothelial cell proliferation** Figure [2a](#Fig2){ref-type="fig"} shows SV-EC counts from ten different patients cultured in 10% FBS with no change in cell number in response to 1--100 nmol/l insulin after 5 days. Similarly, no effect of insulin was seen in cells exposed to 1% FBS (data not shown). When cells were exposed to C-peptide (10 nmol/l) alone, a significant increase in cell number of ∼40% was observed, which was not affected by insulin (Fig. [2b](#Fig2){ref-type="fig"}). Further studies revealed that C-peptide increased SV-EC proliferation at concentrations as low as 0.1 nmol/l (Fig. [2c](#Fig2){ref-type="fig"}). Fig. 2Effect of insulin and C-peptide on human SV-EC proliferation and migration. **a** SV-EC proliferation. Quiesced cells treated with 10% FBS supplemented with 0--100 nmol/l insulin. Cells counted on day 0 and after 5 days with insulin and/or C-peptide treatment. ANOVA: *p* = 0.599 for effect of insulin on day 5 (*n* = 10). Post hoc: all non significant. **b** SV-EC proliferation. Medium supplemented with 10 nmol/l C-peptide alone or in combination with 1--100 nmol/l insulin for 5 days. \*\*\**p* \< 0.001, \*\**p* \< 0.01 (*n* = 4). **c** SV-EC proliferation. Medium supplemented with 0.1--10 nmol/l C-peptide for 5 days. ANOVA: *p* \< 0.001 for effect of C-peptide. Post hoc: \*\**p* \< 0.01, \**p* \< 0.05 (*n* = 6). **d** SV-EC migration. Representative images of wounded endothelial cell monolayers in 10% FBS at 0 h and 24 h. Migration distances of SV-EC in 1% FBS (**e**) or 10% FBS (**f**) with insulin (100 nmol/l), C-peptide (10 nmol/l) or both (*n* = 4). ANOVA with post hoc: all NS

**Endothelial cell migration** In the scratch wound assay, SV-ECs at the wound edge migrate to repopulate a denuded area created by the scratch (Fig. [2d](#Fig2){ref-type="fig"}). Cells exposed to 1% FBS (Fig. [2e](#Fig2){ref-type="fig"}) had half the migratory capacity of cells in 10% FBS (Fig. [2f](#Fig2){ref-type="fig"}). No modulatory effects were observed with either insulin, C-peptide or both together in either 1% or 10% FBS-supplemented media (Fig. [2](#Fig2){ref-type="fig"}e, f).

**Smooth muscle cell proliferation** SV-SMCs from four different patients cultured in control growth medium exhibited a 2.5-fold increase in cell number after 7 days compared with day 0 (Fig. [3a](#Fig3){ref-type="fig"}). C-peptide did not affect cell number observed in the absence of insulin, but supplementation with 10--100 nmol/l insulin further increased SV-SMC proliferation in a concentration-dependent manner (ANOVA *p* \< 0.0001), with 100 nmol/l insulin stimulating a 55% increase in cell number (Fig. [3a](#Fig3){ref-type="fig"}). These mitogenic effects of insulin were prevented by co-incubation with 10 nmol/l C-peptide (Fig. [3a](#Fig3){ref-type="fig"}). The mean number of detached cells observed throughout the proliferation assays was \<1% of the total and was unaffected by any treatment (data not shown). Fig. 3Effect of insulin and C-peptide on human SMC proliferation. Quiesced SMC incubated in medium containing 0.2% FBS + 10 ng/ml platelet-derived growth factor supplemented with insulin and/or C-peptide. Cells counted on day 0 (before additions) and after 7 days unless stated otherwise. **a** SV-SMCs exposed to 0--100 nmol/l insulin alone (white bars) or insulin together with 10 nmol/l C-peptide (black bars). ANOVA: *p* \< 0.0001 for effect of insulin (\*\*\**p* \< 0.001 post hoc); *p* = 0.3084 for effect of insulin + C-peptide (*n* = 4). ^††^*p* \< 0.01, ^†††^*p* \< 0.001 for effect of C-peptide in presence of insulin. **b** IMA-SMCs from the same patients as (a) exposed to 0--100 nmol/l insulin alone (white bars) or insulin together with 10 nmol/l C-peptide (black bars). ANOVA: *p* = 0.3743 for effect of insulin; *p* = 0.7783 for effect of insulin + C-peptide (*n* = 4). Post hoc: all NS. **c** SV-SMCs exposed to control basal medium (black squares) or basal medium supplemented with 100 nmol/l insulin (white squares) or 100 nmol/l insulin plus 10 nmol/l C-peptide (black circles) for 7 days. Cells counted on days 0--4 and 7. Area under curve analysis: control vs insulin, *p* \< 0.01; control vs insulin + C-peptide, *p* \> 0.05; insulin vs insulin + C-peptide, *p* \< 0.05 (*n* = 4). **d** SV-SMCs exposed to 0--10 nmol/l C-peptide alone (white bars) or together with 50 nmol/l insulin (black bars). \**p* \< 0.05; NS, not significant for effect of insulin (*n* = 4). **e** SV-SMCs exposed to medium supplemented without (white bars) or with (black bars) 100 nmol/l insulin in absence ('control') or presence of 10 nmol/l C-peptide or 10 nmol/l scrambled C-peptide. \**p* \< 0.05 (*n* = 5). **f** Human aortic SMCs exposed to control basal medium ('Ctrl') or basal medium supplemented with 10 nmol/l C-peptide, 100 nmol/l insulin, or both together for 7 days. \**p* \< 0.05 (*n* = 3)IMA-SMCs cultured from the same four patients as the SV-SMCs, displayed a 2.1-fold increase in cell number after 7 days treatment in control growth medium (Fig. [3b](#Fig3){ref-type="fig"}), which was lower than that observed for SV-SMCs. In stark contrast to SV-SMCs, insulin (10--100 nmol/l) had no effect on IMA-SMC proliferation, and C-peptide (10 nmol/l) did not modulate proliferation in the presence or absence of insulin (Fig. [3b](#Fig3){ref-type="fig"}).A time course of the effects of insulin and C-peptide on SV-SMC proliferation revealed that the mitogenic effects of insulin, and the attenuating effects of C-peptide, were evident over a 3--7 day period (Fig. [3c](#Fig3){ref-type="fig"}). Comparison of areas under the proliferation curves revealed that cells exposed to insulin proliferated at a higher rate than control cells (*p* \< 0.01) or cells cultured in the presence of both insulin plus C-peptide (*p* \< 0.05). There was no difference in proliferation rates between control cells and those cultured with insulin plus C-peptide. Further studies revealed that C-peptide attenuated insulin-induced SV-SMC proliferation at concentrations as low as 0.1 nmol/l (Fig. [3d](#Fig3){ref-type="fig"}). In contrast to C-peptide, a scrambled version of C-peptide (31-mer with the same amino acid content as C-peptide but in a random order) had no effect on proliferation of SV-SMCs in the absence or presence of insulin (Fig. [3e](#Fig3){ref-type="fig"}).In view of C-peptide's lack of effect on arterial vs venous SMCs, and a previous report that it increased aortic SMC proliferation in the absence of insulin \[[@CR35]\], we investigated the effects of insulin and C-peptide on SMCs cultured from human aortic root (Fig. [3f](#Fig3){ref-type="fig"}). C-peptide increased proliferation of human aortic SMCs (35% increase) in agreement with Walcher et al. \[[@CR35]\]. Insulin alone also stimulated a 28% increase in aortic SMC number. Insulin and C-peptide together showed no additive proliferative response compared with either agent alone (Fig. [3f](#Fig3){ref-type="fig"}), and scrambled C-peptide had no effect (data not shown).

**Smooth muscle cell migration** SMC migration was assessed using Boyden chambers. A significant increase (2.5-fold) was observed in migration towards a 100 nmol/l insulin stimulus (Fig. [4a](#Fig4){ref-type="fig"}). Consistent with C-peptide's effects on neointima formation and SV-SMC proliferation (Figs [1](#Fig1){ref-type="fig"}, [3](#Fig3){ref-type="fig"}), inclusion of 10 nmol/l C-peptide with insulin fully prevented insulin-induced migration of SV-SMCs (Fig. [4a](#Fig4){ref-type="fig"}, *n* = 11 patients). Pre-treatment with inhibitors of the ERK pathway (PD98059) or phosphoinositide 3-kinase (PI3K)/Akt pathway (LY294002) fully prevented insulin-induced migration (Fig. [4b](#Fig4){ref-type="fig"}), indicating essential roles for these signalling pathways. Fig. 4Effect of insulin and C-peptide on SV-SMC migration and signalling. **a** Migration of SV-SMCs from 11 patients towards basal medium (control), or medium supplemented with 100 nmol/l insulin alone, or 100 nmol/l insulin plus 10 nmol/l C-peptide. \*\*\**p* \< 0.001 (*n* = 11). **b** SV-SMC migration towards 100 nmol/l insulin stimulus following pretreatment with 30 μmol/l PD98059 (ERK pathway inhibitor) or 10 μmol/l LY294002 (PI3K/Akt pathway inhibitor). The bar chart depicts the mean number of migrated cells per high power (HP) field. \*\*\**p* \< 0.001 (*n* = 4). **c**, **d** SV-SMCs exposed to serum-free medium (SFM) alone or supplemented with 50 nmol/l insulin and/or 10 nmol/l C-peptide for 15 min before preparing homogenates and immunoblotting for phosphorylated and total Akt (**c**) or ERK (**d**). The bar charts depict densitometric ratios of phospho- to total Akt/ERK from five separate experiments. \*\*\**p* \< 0.001 (*n* = 5)

**Smooth muscle cell signalling** We next investigated whether C-peptide could be acting by inhibiting the ERK or PI3K/Akt pathways, the two major pathways that lie downstream of the insulin receptor. Insulin stimulated phosphorylation of Akt (Fig. [4c](#Fig4){ref-type="fig"}), but ERK phosphorylation was not markedly increased, probably owing to the high basal level of ERK activation in these cells (Fig. [4d](#Fig4){ref-type="fig"}). C-peptide alone or in combination with insulin did not modulate Akt or ERK signalling (Fig. [4c](#Fig4){ref-type="fig"},d). Thus, C-peptide ablates the effects of insulin on SV-SMC function independently of ERK or Akt signalling pathways.

**Smooth muscle cell gene expression** To identify insulin-responsive genes modulated by C-peptide, we used a SYBR-Green-based real-time RT--PCR array to monitor expression of 84 genes involved in insulin signalling, including insulin-receptor-associated proteins, components of the ERK and Akt pathways, insulin-responsive genes, transcription factors and genes involved in carbohydrate and lipid metabolism. SV-SMCs from six patients were treated with or without 100 nmol/l insulin for 6 h before extracting RNA. Concomitant migration assays were performed to confirm the functional effects of insulin and C-peptide on SV-SMC migration (Fig. [5a](#Fig5){ref-type="fig"}). Fig. 5Effect of insulin and C-peptide on SV-SMC gene expression. **a** SV-SMC migration towards 100 nmol/l insulin in the absence or presence of C-peptide (10 nmol/l). \*\*\**p* \< 0.001 (*n* = 6). **b** SV-SMC from the same six patients with 100 nmol/l insulin for 6 h before extracting RNA and performing PCR array. Data expressed as volcano plot in which the *x*-axis depicts changes in mRNA levels (increases to the right of the origin, decreases to the left), and *y*-axis depicts statistical significance. Full data are available as ESM (Table [1](#MOESM1){ref-type=""}). **c**, **d** Real-time RT--PCR data of *SREBF1* or *IGF1R* mRNA levels following 6 h treatment of SV-SMCs with 100 nmol/l insulin alone or together with 10 nmol/l C-peptide as percentage of *HPRT1* housekeeping gene mRNA levels. \*\**p* \< 0.01, \*\*\**p* \< 0.001 (*n* = 6). **e**, **f** Real-time RT--PCR of *SREBF1* or *IGF1R* mRNA levels following 1--6 h treatment of SV-SMC with 100 nmol/l insulin alone (white bars) or together with 10 nmol/l C-peptide (black bars) (*n* = 3). Data are expressed relative to *HPRT* levels and normalised to 0 h sample. *SREBF* ANOVA: *p* = 0.004 for effect of insulin alone (\**p* \< 0.05 post hoc); *p* = 0.713 for effect of insulin + C-peptide. ^+^*p* \< 0.05 for effect of C-peptide in presence of insulin. *IGFR1* ANOVA: *p* = 0.018 for effect of insulin alone (\**p* \< 0.05 post hoc); *p* = 0.026 for effect of insulin + C-peptide (\**p* \< 0.05 post hoc). There was no significant effect of C-peptide in the presence of insulinData are presented in Fig. [5b](#Fig5){ref-type="fig"} as a volcano plot with full data included in the Electronic supplementary material (ESM) Table [1](#MOESM1){ref-type=""}. We selected four genes for further study based on changes in transcript levels and reproducibility (statistical significance): namely *IGF1R*, *SORBS1*, *GLUT4* and *SREBF1*.Taqman primer/probe sets were utilised to confirm array data using the same RNA samples. The insulin-induced increase in *SREBF1* mRNA expression and decrease in *IGF1R* mRNA expression were confirmed by RT--PCR (Fig. [5c](#Fig5){ref-type="fig"},d). However, the array data could not be confirmed for *SORBS1* or *GLUT4* (data not shown).Insulin-induced *SREBF1* mRNA expression was fully prevented by co-incubation with C-peptide (Fig. [5c](#Fig5){ref-type="fig"}). By contrast, the effect of insulin on *IGF1R* expression was not modulated by C-peptide (Fig. [5d](#Fig5){ref-type="fig"}). The acute temporal profiles of *SREBF1* and *IGF1R* mRNA expression in response to insulin, with or without C-peptide, were then determined over the 6 h period (Fig. [5e](#Fig5){ref-type="fig"},f). Insulin-induced *SREBF1* mRNA expression was evident after 3 h and rose thereafter, reaching a 40% increase after 6 h (ANOVA, *p* \< 0.01) (Fig. [5e](#Fig5){ref-type="fig"}). No increase in *SREBF1* mRNA levels was apparent when C-peptide was present with insulin (ANOVA, *p* = 0.713) (Fig. [5e](#Fig5){ref-type="fig"}). In contrast to *SREBF1*, the insulin-induced decrease in *IGF1R* mRNA expression after 2--6 h (ANOVA, *p* \< 0.05) was not modulated by C-peptide (Fig. [5f](#Fig5){ref-type="fig"}).

Effect of SREBF1 gene silencing on SV-SMC migration {#Sec4}
---------------------------------------------------

The above data implicated SREBF1 as a molecular target for the antagonistic effects of C-peptide on insulin-induced SV-SMC proliferation and migration. To confirm that *SREBF1* expression was involved in insulin-induced SV-SMC migration, we employed a gene-silencing approach. SREBF1 protein production was markedly reduced 24--72 h following siRNA transfection, although a return of production was evident at the 96 h time point (Fig. [6a](#Fig6){ref-type="fig"}). *SREBF1* gene silencing had no effect on basal SV-SMC migration but specifically prevented insulin-induced migration, to a level comparable with the inhibition achieved with C-peptide (Fig. [6b](#Fig6){ref-type="fig"}). *SREBF1* knockdown had no modulatory effect on insulin-induced cell migration in the presence of C-peptide, suggesting that C-peptide and *SREBF1* siRNA may be acting on the same target i.e. reducing *SREBF1* expression. Thus, insulin-induced SV-SMC migration requires *SREBF1* expression, and the ability of C-peptide to prevent insulin-induced migration may be explained through a reduction in *SREBF1* expression. Fig. 6Effect of *SREBF1* gene silencing on insulin-induced SV-SMC migration. Cells were mock-transfected or transfected with *SREBF1*-targeted siRNA before measuring SREBF1 protein and SV-SMC migration. **a** Immunoblot showing SREBF1 protein production 24--96 h after transfection with or without *SREBF1* siRNA. The arrow indicates the position of the SREBF1 band (125 kDa). **b** Migration assay showing effects of *SREBF1* gene silencing (36 h) on SV-SMC migration towards basal medium (control; white bars), or medium supplemented with 100 nmol/l insulin alone (black bars) or together with 10 nmol/l C-peptide (hatched bars). \*\**p* \< 0.01, \*\*\**p* \< 0.001 (*n* = 6)

Discussion {#Sec5}
==========

The principal finding of our study was that neointima formation in organ-cultured human SVs was increased in the presence of insulin, an effect abrogated by proinsulin C-peptide. Neointima formation requires SMC migration and proliferation, both of which were induced by insulin and fully inhibited by C-peptide. The effects of C-peptide were not a result of inhibition of insulin-mediated Akt and ERK signalling, but were related to reduced insulin-induced *SREBF1* expression.

In agreement with earlier studies \[[@CR15], [@CR18]\] we revealed a causative role for insulin in neointima formation but importantly demonstrated a counter-regulatory effect of C-peptide. Our model mimics the situation of insulin-treated diabetes, with the presence of insulin but not C-peptide, and suggests that co-supplementing insulin with C-peptide could provide a better treatment than insulin alone.

Damage to the SVs during harvesting and implantation inevitably induces endothelial dysfunction, a feature associated with neointima formation. As effective re-endothelialisation is known to inhibit neointimal hyperplasia \[[@CR36]\], we investigated whether insulin and/or C-peptide could modulate EC migration and/or proliferation. Insulin did not alter EC proliferation, whereas C-peptide induced an increase, an effect maintained in the presence of insulin. Migration was not affected by either insulin or C-peptide. Thus, C-peptide acts directly on SMCs to prevent neointima formation while increasing EC proliferation to promote re-endothelialisation \[[@CR36]\].

In agreement with a previous study \[[@CR37]\], insulin increased migration of SV-SMCs via ERK and PI3K/Akt pathways. However, C-peptide's counter-regulation was not due to inhibition of these pathways. The mode of action of C-peptide is unknown, although it binds to human cell membranes \[[@CR38]\] and its target may be a G-protein-coupled receptor in some tissues \[[@CR39]\]. C-peptide has been shown to internalise in Swiss 3T3 and HEK 293 cells \[[@CR40]\], and a very recent study in human aortic ECs and umbilical artery SMCs indicated that C-peptide was internalised by early endosomes \[[@CR41]\]. Whether the endosomal pathway is functional in human SV-SMCs and required for C-peptide trafficking will require elucidation in future studies. Importantly, our data do not support speculation that C-peptide binds to the insulin receptor \[[@CR42]\]. Thus, in human SV-SMCs, C-peptide acts independently of the insulin receptor and its immediate downstream signalling pathways.

Insulin increased SV-SMC proliferation in a concentration-dependent manner. C-peptide even at very low concentration abolished these effects, consistent with its activity at nanomolar concentrations found in plasma \[[@CR43]\] and full saturation of C-peptide binding sites at low nanomolar concentrations \[[@CR38]\].

In the vasculature, the reported effects of C-peptide are at variance and potentially explained by different experimental approaches. Two previous studies have claimed that C-peptide reduces SMC proliferation. One report used rat SMCs and human C-peptide and saw a modest effect on high glucose-induced (25 mmol/l) proliferation, but only after 3 weeks \[[@CR44]\]. A more recent study using human arterial SMCs also observed increased proliferation with high glucose culture that was attenuated by C-peptide \[[@CR45]\]. By contrast, our data differ from those reporting a mitogenic effect of C-peptide on human and rat aortic SMCs \[[@CR35]\], in which C-peptide was coupled to activation of PI3K/Akt and ERK pathways, which were not modulated by C-peptide in our study using SV-SMCs. This raises the intriguing possibility that C-peptide has opposing effects on SMCs from different vascular beds. To test this, we cultured human aortic SMCs and found that C-peptide was pro-proliferative, in agreement with the findings of Walcher et al. \[[@CR35]\]. However, when aortic SMCs were cultured in the presence of insulin, itself a mitogen, no additive effect of C-peptide was observed. Unlike our present study, in none of the above studies was the effect of insulin investigated. It is also important to note that in individuals without diabetes C-peptide is only ever present with insulin. The findings of all these reports can therefore be reconciled by taking into account species and source of SMCs, together with insulin, C-peptide and glucose concentrations.

In contrast to the SVs, IMA grafts provide better long-term patency even in diabetic patients \[[@CR46]\], indicating resistance to restenosis. This remarkable difference in patency between conduits is clearly multifactorial, but we have previously shown that SV-SMCs are inherently more proliferative than IMA-SMCs from the same patients \[[@CR32]\]. In direct contrast to SV cells, insulin did not promote IMA-SMC proliferation, which may help explain the similar patency rates of IMA grafts in insulin-treated patients compared with those in non-diabetic patients \[[@CR46]\]. The inability of insulin to induce IMA-SMC proliferation was not due to lack of insulin signalling, as both Akt and ERK phosphorylation were evident in insulin-treated IMA-SMCs (data not shown). These data highlight the importance of using relevant cell types and add to the concept of cell-type-specific effects of both insulin and C-peptide.

Having established the effects of insulin and C-peptide on SV-SMC migration and proliferation, we used an insulin signalling array to identify potential molecular mechanisms. *SREBF1* mRNA expression was increased in response to insulin; an effect attenuated by C-peptide. *SREBF1* gene silencing selectively attenuated the insulin-induced component of SV-SMC migration, strongly suggesting that the ability of C-peptide to reduce SV-SMC migration is due to inhibition of insulin-induced *SREBF1* expression. SREBF1 (SREBP1) is a member of the basic helix-loop-helix-leucine zipper (bHLH-Zip) family of transcription factors that regulate lipid and carbohydrate metabolism \[[@CR47]\]. A role for SREBF1 in proliferation of murine aortic SMCs is reported \[[@CR48]\]. SREBF1, by regulating lipid and cholesterol biosynthesis, may play a role in plasma membrane synthesis and could optimise membrane properties for SV-SMC migration and proliferation in response to insulin. Importantly, these effects of insulin can be abrogated by C-peptide.

Vascular SMC proliferation is induced by a plethora of growth factors and cytokines, and additionally hyperinsulinaemia has been implicated as an important risk factor for atherosclerotic lesion formation in diabetic patients through increased SMC proliferation \[[@CR49]\]. Here we have shown that insulin and its C-peptide differ in their effects on cells from different vascular beds. These peptides are normally secreted in equimolar amounts but this relationship is perturbed when exogenous, recombinant insulin is administered to replace natural synthesis.

A potential limitation of our study was the use of 100 nmol/l insulin: a supraphysiological concentration when compared with that observed in vivo after a meal in normal (∼0.3--0.4 nmol/l) or insulin-resistant (∼1.4--1.5 nmol/l) individuals. Relatively high concentrations of insulin are often required in vitro to observe functional effects, probably reflecting the numerous differences between in-vitro functional assays and the situation in vivo*.* Lower concentrations of insulin (e.g. 25 nmol/l) also resulted in increased SV-SMC proliferation in our experiments (Fig. [3a](#Fig3){ref-type="fig"}), but we selected the 100 nmol/l concentration based on the reproducibility and magnitude of its effects. One strength of our study was the use of cells from multiple patients. Interestingly, C-peptide had maximal effects on SV-EC and SV-SMC proliferation at concentrations as low as 0.1 nmol/l (Figs [2c](#Fig2){ref-type="fig"}, [3d](#Fig3){ref-type="fig"}): levels of C-peptide that are physiologically relevant.

During the last decade there has been a wealth of new information regarding the impact of C-peptide on a variety of cell types and specific cell functions. However, until recently the major focus has been on the microvascular complications of type 1 diabetes \[[@CR50]\], with its effects in type 2 diabetes being less well explored. It is generally perceived that C-peptide is beneficial (for reviews see \[[@CR51], [@CR52]\]), although the mechanisms underlying such effects appear to be tissue- and cell-type specific, and insulin is not always necessary for C-peptide to function. Indeed, our own data, for example, indicate a differential effect of C-peptide on SMCs from aorta and SV. In this respect, elucidation of the specific mechanisms underlying the functional effects of C-peptide in relevant cell types is of key importance.

In summary, our study is the first to report a direct modulatory effect of proinsulin C-peptide on the potentially deleterious effects of insulin on human SV neointima formation, through effects on both SMC and EC function. Our data implicate SREBF1 as a candidate for further investigation. Co-administration of C-peptide with insulin may improve SV bypass graft patency rates in insulin-treated diabetic patients. Clinical trials will be necessary to test this hypothesis.
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EC

:   Endothelial cell

ERK

:   Extracellular signal-regulated kinase

HPRT1

:   Hypoxanthine phosphoribosyltransferase 1

IGF1R

:   IGF 1 receptor

IMA

:   Internal mammary artery

PI3K

:   Phosphoinositide 3-kinase

SMC

:   Smooth muscle cell

SORBS1

:   Sorbin and SH3 domain containing protein 1

SREBF1

:   Sterol regulatory element binding transcription factor 1

SV

:   Saphenous vein
